China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment

China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment

China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic chronic heart failure (HF). This follows an earlier authorization for patients suffering from heart failure with reduced ejection fraction (HFrEF). Now, Forxiga’s capabilities extend to all adults with symptomatic chronic […]

AstraZeneca Pharma India gets Dapagliflozin 10mg import and market permission from CDSCO

AstraZeneca Pharma India gets Dapagliflozin 10mg import and market permission from CDSCO

AstraZeneca Pharma India has secured an import and market permission for Dapagliflozin (Forxiga) tablets of 10 mg from India’s Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services. Following the approval, AstraZeneca Pharma India is now allowed to deal in Dapagliflozin 10 mg in additional/expanded indication for lowering the risk of sustained eGFR […]

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in India. As per an agreement signed in late 2018, Abbott Healthcare had been promoting and distributing Dapagliflozin under the “Gledepa” brand name and the Dapagliflozin and Metformin combination under the […]

AstraZeneca’s Forxiga wins approval in China for heart failure treatment

AstraZeneca’s Forxiga wins approval in China for heart failure treatment

AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]